What have we learned from the <scp>REPRIEVE</scp> trial and where do we go from here?-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

What have we learned from the REPRIEVE trial and where do we go from here?

Published:2024-08-25 Issue: Volume: Page:
ISSN:1464-2662
Container-title:HIV Medicine
language:en
Short-container-title:HIV Medicine

Author:

Grinspoon Steven K.¹,Lu Michael T.²,Zanni Markella V.¹,Diggs Marissa R.¹,Chu Sarah M.¹,Ribaudo Heather J.³,Douglas Pamela S.⁴

Affiliation:

1. Metabolism Unit Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA

2. Cardiovascular Imaging Research Center, Department of Radiology Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA

3. Center for Biostatistics in AIDS Research, Harvard T.H. Chan School of Public Health Boston Massachusetts USA

4. Duke Clinical Research Institute Duke University School of Medicine Durham North Carolina USA

Funder

National Institutes of Health

Kowa Pharmaceutical

Gilead Sciences

ViiV Healthcare

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/hiv.13703

Reference18 articles.

1. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV

2. HIV Infection and the Risk of Acute Myocardial Infarction

3. Epidemiology of ischemic heart disease in HIV

4. Coronary Plaque in People With HIV vs Non-HIV Asymptomatic Community and Symptomatic Higher-Risk Populations

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP